Purchase Order 75N91018P00718

This is a $65,800 firm-fixed-price purchase order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Repeat Diagnostics Inc., a for-profit limited liability company based in Ottawa, Canada. The contract is for laboratory services to perform telomere length measurement using a 6-panel flow fluorescence in situ hybridization (flow-FISH) assay. This contract supports NCI's research into the correlation between telomere length and...

<p>The National Heart Lung and Blood Institute awarded a purchase order to Repeat Diagnostics Inc. for $34,800 on December 5, 2017 for flow-FISH 2-panel telomere length measurements, with completion due December 10, 2018. Performance occurs at 2323 Riverside Drive, Ottawa, Ontario, Canada. The order is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Nexome Genomics Inc. for customized FISH probe panels, valued at $16,800.00, on December 9, 2019. Performance is located in Bethesda, Maryland. The order carries firm fixed price terms and an ultimate completion date of January 9, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Fujirebio US, Inc. on August 29, 2017, for $14,510.26, with completion due December 29, 2017. Performance is at Fujirebio's Malvern, Pennsylvania location. The order covers medical diagnostic equipment, reagents, assay kits, and related scientific instruments supporting the Institute's research requirements under the firm fixed-price structure of covering order 261201600324P, 16-029956.</p>

<p>The National Heart Lung and Blood Institute awarded a purchase order to Repeat Diagnostics Inc. for $34,800 on March 14, 2017. The order covers 2-panel flow-FISH testing services with an ultimate completion date of March 13, 2018. Performance occurs in Bethesda, Maryland. The pricing is firm fixed price with no small business set-aside.</p>

<p>The National Cancer Institute issued a delivery order to Repeat Diagnostics Inc. on December 18, 2015, with a ceiling value of $4,450.00 for laboratory testing services of telomere length assays supporting the Inherited Bone Marrow Failure Study.</p> <p>Place of performance is Rockville, Maryland. The order was firm fixed price with an ultimate completion date of May 26, 2021. The award involved de-obligation of funds from expiring FY2016 lines and was issued under no set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Interpflow Corporation for $14,875.00 on August 6, 2019, for laboratory testing. Work is performed at Bethesda, Maryland, with an ultimate completion date of August 31, 2019. The contract is priced as firm fixed price with no set-aside used.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $12,768.84 on September 11, 2018, with completion scheduled for September 18, 2019. Pricing is fixed-price with economic price adjustment. Place of performance is Bethesda, Maryland. The source does not identify the specific items or services procured under this order.</p>

<p>The National Cancer Institute issued a delivery order to Roche Diagnostics Corporation on October 21, 2015, with a ceiling value of $37,811.40 for in vitro diagnostic products and services.</p> <p>Place of performance is Bethesda, MD. The order was firm fixed price with an ultimate completion date of December 9, 2019. No set-aside was used.</p>

<p>The National Cancer Institute issued a $26,365.32 delivery order to Roche Diagnostics Corporation on April 14, 2016, for in vitro diagnostic products and laboratory instruments.</p> <p>Place of performance is Bethesda, MD. The order was firm fixed price with no set-aside designation and an ultimate completion date of April 14, 2016.</p>